[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-without-type-2-diabetes-with-weight-related-comorbidities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-without-type-2-diabetes-with-weight-related-comorbidities":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100639469","effectiveness-of-combined-glp-1gip-dual-agonist-therapy-and-structured-exercise-on-skeletal-muscle-morphology-quality-and-physical-function-in-overweight-and-obese-individuals-100639469",false,"NCT07609160","Effectiveness of Combined GLP-1\u002FGIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals","Effectiveness of Combined GLP-1\u002FGIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals: a Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist,\n* body mass index (BMI) ≥27 kg\u002Fm² and the presence of a comorbidity condition or BMI≥30 kg\u002Fm²\n* age between 18 and 65 years\n\nExclusion Criteria:\n\n* diagnosis of type 1 or type 2 diabetes mellitus\n* presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders\n* current participation in a structured diet or exercise program\n* use of weight-loss medications within the past 12 months\n* history of upper or lower extremity surgery or injury within the past 6 months\n* any contraindication to resistance exercise as determined by the treating physician.","ALL","18 Years","65 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.",[27,28,29],"Obesity","Sarcopenia","Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities",[31,32,33,34],"exercise","physical activity","muscle","physical function","NOT_YET_RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":21},"2026-11-01",{"date":43,"type":21},"2028-01-01",{"name":45,"class":46},"Acibadem University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100629982","phase-3-efficacy-and-safety-of-tirzepatide-once-weekly-versus-placebo-in-participants-who-are-either-obese-or-overweight-with-weight-related-comorbidities-surmount-1-100629982","NCT07481747","Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)","SURMOUNT-1","Inclusion Criteria:\n\n* BMI ≥30 kg\u002Fm², OR BMI ≥27 kg\u002Fm² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)\n* History of at least one unsuccessful dietary effort to lose weight (self-reported)\n* Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires\n* Age ≥18 years\n* Meets protocol contraception\u002Fpregnancy criteria (as applicable) and provides written informed consent\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes, history of ketoacidosis\u002Fhyperosmolar state, or screening labs diagnostic of diabetes\n* Recent significant weight change (\\>5 kg within 3 months prior to screening)\n* Prior\u002Fplanned bariatric surgery; recent\u002Fongoing endoscopic or device-based obesity therapies\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Clinically significant gastric emptying abnormality or chronic use of drugs that directly affect GI motility\n* History of chronic or acute pancreatitis\n* Clinically significant thyroid abnormalities at screening (e.g., TSH outside protocol range) or anticipated need to initiate thyroid replacement during study\n* Obesity due to other endocrinologic disorders (e.g., Cushing syndrome) or monogenic\u002Fsyndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome)\n* Significant unstable major depressive disorder\u002Fsevere psychiatric disorder, lifetime suicide attempt, or concerning suicidality screening (PHQ-9\u002FC-SSRS criteria)\n* Uncontrolled hypertension; recent major cardiovascular events; NYHA class IV heart failure\n* Active or significant liver disease or certain elevated liver tests at screening (per protocol thresholds)\n* Elevated calcitonin above protocol thresholds; personal\u002Ffamily history of medullary thyroid carcinoma or MEN2\n* Active\u002Funtreated malignancy or remission \\\u003C5 years (with specified exceptions)\n* Any other condition contraindicating GLP-1 receptor agonist therapy",{"count":56,"type":21},2539,[58],"PHASE3","This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.",[27,29],[62,63,64,65,66,67,68,69,70,71,72,73,74,75],"Tirzepatide","LY3298176","dual incretin","GIP","GLP-1","obesity","overweight","weight management","placebo","randomized","double-blind","once-weekly","subcutaneous","lifestyle intervention","RECRUITING","2026-03-14",{"date":79,"type":39},"2026-03-19",{"date":81,"type":39},"2026-02-02",{"date":83,"type":21},"2028-03-17",{"name":85,"class":86},"Hudson Biotech","INDUSTRY",1]